Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
Zymeworks To Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
Dr. Raffaele Colombo Honored as a PharmaVoice 100 Winner
Zymeworks is thrilled to announce that Dr. Raffaele Colombo has been honored as a PharmaVoice 100 winner. This annual list recognizes the most inspiring people in the life sciences industry. Dr. Colombo has been instrumental in the advancement of Zymeworks’ wholly-owned pipeline, leveraging his experience and knowledge towards the development of a portfolio of novel […]
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
